Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Recurrent UTIs impact eGFR in children with vesicoureteral reflux

2.

Advanced imaging, targeted therapy help men with prostate cancer safely defer surgery and radiation therapy

3.

Prostate cancer 'is not a death knell': Early detection and personalized care improve outcomes, study shows

4.

Guideline on management of early-stage non-small cell lung cancer released

5.

Can Oligonucleotide Infusions Really Fix Lyme, Cancer, and Other Diseases?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot